Semaglutide is the only GLP-1 receptor agonist approved as both an oral tablet and a subcutaneous injection, sold under three brand names that split the diabetes and weight-management indications.
Semaglutide is the only GLP-1 receptor agonist sold as both an oral tablet and a subcutaneous injection, marketed under three brand names that split two distinct indications: Ozempic and Rybelsus for type 2 diabetes, Wegovy for chronic weight management. Ozempic and Wegovy each now come in both an injectable pen and an oral tablet of their own, and Wegovy also has a separate higher-dose HD pen, so the oral-versus-injectable choice runs within each indication rather than across brand lines. M Care Exports sources finished, licensed semaglutide product from WHO-GMP certified Indian manufacturers and quotes to the buyer's own registered brand, form, strength and destination label, never to a compounded or unlicensed equivalent.
Semaglutide exporter and bulk supplier from India.
Export packing for semaglutide splits by presentation rather than by brand. Injectable pens (Ozempic, Wegovy, Wegovy HD) ship as a validated cold-chain consignment, packed at 2 to 8 degrees C with qualified insulated shippers, phase-change or gel refrigerant, and a temperature data logger per shipment; each brand's in-use storage window after first use is documented separately at handover so the buyer's receiving pharmacy can label correctly. Oral tablets (Rybelsus, Ozempic Tablets, Wegovy Tablets) ship at controlled room temperature in their original moisture-protected blister packaging, since the SNAC absorption-enhancer formulation is moisture-sensitive. Every consignment carries a batch-specific certificate of analysis, certificate of origin, and the source manufacturer's GMP documentation, aligned to the importing country's cold-chain and pharmacovigilance requirements. Availability by brand, form, strength and batch is confirmed at enquiry.
Source
WHO-GMP-certified Indian manufacturing line, named on every quote.
Minimum order
No blanket MOQ. Set by the source manufacturer's minimum batch-release quantity for the strength and pack ordered.
Pricing
On request. Indicative FOB or CIF quote, formal proforma on confirmation.
Incoterms
EXW, FOB, CIF, CIP or DAP.
Payment
Letter of credit (sight or usance) and telegraphic transfer.
Documentation
WHO-GMP certificate of the source line, product-specific CoPP, batch CoA, method of analysis, Free Sale Certificate, Certificate of Origin, CTD or eCTD dossier. On request.
Shelf-life
Minimum remaining shelf-life agreed per order and confirmed on the proforma.
Response
Availability and CoPP status within two working days; pre-alert documents before dispatch.
GLP-1 receptor agonist (glucagon-like peptide-1 receptor agonist), sourced and documented for export.
Semaglutide is the only GLP-1 receptor agonist available in both an oral tablet and a subcutaneous injection pen, a formulation split with real handling and dosing consequences, and one that now runs across all three of its brand names rather than separating them. Rybelsus, the original oral tablet, uses an absorption enhancer called SNAC to make a peptide bioavailable by mouth, and must be taken on an empty stomach with minimal water, with a 30-minute gap before food, drink or other oral medicines, or absorption drops sharply; Ozempic Tablets and Wegovy Tablets, both introduced more recently, use the same SNAC-based technology and the same administration rule under their own brand names and strengths. The injectable pens (Ozempic for type 2 diabetes, and Wegovy plus the higher-dose Wegovy HD pen for chronic weight management) are dosed once weekly and titrated upward over several weeks to the maintenance strength; none of these presentations is interchangeable with another's indication or dose ladder. Every semaglutide product carries the same boxed warning for thyroid C-cell tumor risk seen in rodent studies, and the injectable pens require cold-chain handling before first use while the tablets do not.
Active ingredient
Semaglutide. GLP-1 receptor agonist (glucagon-like peptide-1 receptor agonist).
Forms and strengths
0.25 mg; 0.5 mg; 1 mg; 1.5 mg; 1.7 mg; 2 mg; 2.4 mg; 3 mg; 4 mg; 7 mg; 7.2 mg; 9 mg; 14 mg; 25 mg.
Indications
Semaglutide is a GLP-1 receptor agonist marketed as Ozempic, injectable pen and, since 2026, an oral tablet, and Rybelsus, oral tablet, for type 2 diabetes, and as Wegovy, injectable pen, a separate higher-dose HD pen, and, since late 2025, an oral tablet, for chronic weight management. It is the only GLP-1 receptor agonist available in both a once-weekly subcutaneous injection and an oral tablet.
Administration
Subcutaneous injection, Oral. Subcutaneous injection pen (prefilled), including a separate higher-dose pen, and oral tablet, in brand-specific strengths.
Documentation
Batch-specific CoA, CoPP, manufacturing-site WHO-GMP certificate and stability data compiled per consignment, in the format the destination regulator expects.
Hospital pharmacies, licensed importers and tender desks across our export markets.
India is our origin. We do not sell into the Indian market.
Buyers for semaglutide fall into two groups that should not be confused: hospital and endocrinology procurement ordering Ozempic, in pen or tablet form, or Rybelsus for type 2 diabetes formularies, and weight-management clinics, pharmacy chains and tender desks ordering Wegovy, Wegovy HD or Wegovy Tablets under their own registrations. M Care Exports supplies licensed importers, wholesalers, hospital procurement and government tender desks across the United Kingdom, the European Union, the Gulf and GCC, Africa, Latin America, Southeast Asia and the CIS states. Each region registers semaglutide brands, forms and strengths separately, and a Wegovy registration does not cover an Ozempic order, nor does a pen registration cover the equivalent tablet, so buyers should confirm the brand, form and indication named in their tender or import licence. India is the country of manufacture only, not a served market.
GCC registration routes
Supply against MoH registration held by your local licensed importer, or via the GCC central registration pathway.
UK unlicensed routes
Where no UK licence exists, the MHRA Specials and named-patient import routes cover clinically justified demand.
Tender desks
Bid-pack documentation assembled to the tender's specification, from CoPP to batch records.
Dossier support
CTD documentation from the sourcing manufacturer, compiled for your regulator's format.
What the dispensing pharmacist checks on semaglutide.
A clinical pharmacist reviewing a semaglutide order should first confirm indication and form match: Ozempic, in pen or tablet form, and Rybelsus are registered for type 2 diabetes; Wegovy, Wegovy HD and Wegovy Tablets are registered for chronic weight management; none of these presentations is interchangeable by dose despite sharing the same molecule. For the injectable pens, check that the pen's fixed dose selector matches the strength ordered (0.25 mg, 0.5 mg, 1 mg, 1.7 mg, 2 mg or 2.4 mg), since several pens are visually similar; Wegovy HD's 7.2 mg strength is a separate, higher-dose pen for patients who have already completed at least 4 weeks on the 2.4 mg maintenance dose, not a titration step toward it. For the oral tablets (Rybelsus at 3 mg, 7 mg or 14 mg; Ozempic Tablets at 1.5 mg, 4 mg or 9 mg; Wegovy Tablets at 1.5 mg, 4 mg, 9 mg or 25 mg), confirm the dispensing instruction covers administration on an empty stomach with no more than 120 mL of water and a 30-minute wait before food, drink or other oral medicines, because co-administered tablets absorbed with it will underperform. Cross-check the boxed warning: personal or family history of medullary thyroid carcinoma or Multiple Endocrine Neoplasia syndrome type 2 is a contraindication across every semaglutide brand and form. Confirm the consignment is finished, licensed product from a named manufacturer, not a compounded or salt-form preparation, which carries a distinct and less predictable safety profile.
The documentation pack a regulator actually asks for.
The documentation pack for semaglutide starts with a batch-specific certificate of analysis and certificate of origin from the source manufacturer, matched to the exact brand, form, strength and pen or tablet configuration ordered, since Ozempic, Ozempic Tablets, Rybelsus, Wegovy, Wegovy HD and Wegovy Tablets are separately registered products even though the active ingredient is identical. M Care Exports sources only from manufacturers holding current WHO-GMP certification for the semaglutide line supplied, and passes that certification through with the order; M Care Exports itself holds ISO 9001:2015 certification and a CDSCO export licence, and does not hold, and will not claim, WHO-GMP or WHO-PQ certification in its own name, since it is a merchant-exporter and not the manufacturing site. For the injectable pens, the pack includes cold-chain validation data and shipment temperature logger records covering transit at 2 to 8 degrees C. Buyers handling a weight-management tender should separately confirm the destination market's registration status for the specific Wegovy presentation required (standard pen, Wegovy HD or Wegovy Tablets), since some markets register the older diabetes brands, or the standard pen, ahead of the newer presentations.
CoA and MoA, per batch
Batch-specific certificate and method of analysis from the sourcing manufacturer's QC release.
CoPP, WHO-GMP, MFG licence
Certificate of pharmaceutical product and site GMP certification issued via CDSCO channels, naming the actual manufacturing site.
CTD Module 3
Chemistry, manufacturing and controls documentation available from the sourcing manufacturer for registration filings.
Pack insert, labels, artwork
Destination-language patient information and labelling to the local regulator's standard, locked before shipment.
Pharmacovigilance
A named PV contact arranged in the destination market where the registration requires one.
What a buyer should know before this line enters a formulary.
We publish the awkward facts alongside the useful ones. A supplier who omits them is not saving you work, only deferring it.
Prescription-only medicine in all destination markets; not for over-the-counter supply
Boxed warning: risk of thyroid C-cell tumors observed in rodent studies; contraindicated in patients with personal or family history of medullary thyroid carcinoma or Multiple Endocrine Neoplasia syndrome type 2; applies to every semaglutide brand and form, including the tablets
Ozempic, in pen or tablet form, and Rybelsus are registered for type 2 diabetes; Wegovy, Wegovy HD and Wegovy Tablets are registered for chronic weight management; brands, forms and strengths are not interchangeable across indication
Cold-chain product for the injectable pens (2 to 8 degrees C transit); defined in-use storage window after first use differs by brand and must be validated to destination
Oral tablets (Rybelsus, Ozempic Tablets, Wegovy Tablets) are moisture-sensitive and must remain in original blister packaging until use; ambient storage, no cold chain required
Not indicated for type 1 diabetes or diabetic ketoacidosis
Adjacent lines procurement desks order alongside semaglutide.
Dapagliflozin metformin
Another diabetes & endocrine line ordered on the same formularies.
Gliclazide
Another diabetes & endocrine line ordered on the same formularies.
Glimepiride
Another diabetes & endocrine line ordered on the same formularies.
All diabetes & endocrine
The full category listing for procurement desks.
Molecule · strength · volume · destination. One working day to a quote.
- Send us the specifics. Form and strength, pack preference, destination market and indicative volume for semaglutide.
- We route to the right line. The enquiry goes to the WHO-GMP certified manufacturing partner whose certificates fit your regulator.
- Commercial and regulatory offer. FOB or CIF price with the documentation list, named manufacturing site and current certificate validity.
- Order, produce, release, ship. QC release on the Indian side, batch documents compiled, despatch on the agreed incoterm.
- After delivery. Batch records and certificates archived and retrievable for the life of the product on your shelf.
Semaglutide supply, the specific questions.
Which semaglutide brand should we reference for a type 2 diabetes tender versus a weight-management tender?
Ozempic, in pen or tablet form, and Rybelsus are registered for type 2 diabetes; Wegovy, Wegovy HD and Wegovy Tablets are registered for chronic weight management. They are not interchangeable on a tender even though the active ingredient is the same molecule, because each carries its own approved strengths, titration schedule and indication wording. Name the brand, form and indication in your enquiry so we quote to the correct registered label.
Does M Care Exports supply the oral tablets as well as the injectable pens?
Yes. We source oral tablets, Rybelsus and the newer Ozempic Tablets and Wegovy Tablets, and injectable pens, Ozempic, Wegovy and Wegovy HD, from WHO-GMP certified manufacturers, and quote to whichever brand, form, strength and registration your tender specifies. The forms have different handling requirements: the tablets are ambient and moisture-sensitive, the pens are cold-chain, and we pack each accordingly.
What is the boxed warning on semaglutide products and who is contraindicated?
Every semaglutide brand and form carries a boxed warning for thyroid C-cell tumors observed in rodent studies; human relevance has not been established. The products are contraindicated in patients with a personal or family history of medullary thyroid carcinoma or Multiple Endocrine Neoplasia syndrome type 2. This is a prescriber-level clinical decision, not a supply restriction.
How does storage differ between the injectable pens and the oral tablets?
The injectable pens (Ozempic, Wegovy, Wegovy HD) require 2 to 8 degree C cold chain before first use, with a defined room-temperature or refrigerated window after opening that differs by brand. The oral tablets (Rybelsus, Ozempic Tablets, Wegovy Tablets) are stored at controlled room temperature in their original moisture-protected blister packaging and do not require refrigeration. We pack and document each presentation to its own storage profile.
What is Wegovy HD and how does its 7.2 mg dose differ from the standard Wegovy titration schedule?
Wegovy HD is a separate, FDA-approved higher-dose pen delivering 7.2 mg once weekly. It is not part of the standard titration schedule that ends at the 2.4 mg maintenance dose; it is intended only for patients who have already completed at least 4 weeks on 2.4 mg and need additional weight loss. Treat it as its own registered presentation, distinct from standard Wegovy, when confirming a destination market's registration and a tender's product description.
Does M Care Exports supply compounded or salt-form semaglutide?
No. We supply finished, licensed semaglutide product manufactured under the approved brand name and formulation only, never a compounded preparation or an alternative salt form such as semaglutide sodium or semaglutide acetate. The FDA has documented compounded and salt-form semaglutide as a safety concern in this market, and sourcing only licensed finished product from licensed manufacturers is a deliberate part of how we operate.
Global demand for GLP-1 medicines has been high. What should we ask about continuity of supply?
Ask about the specific manufacturer's current production allocation for the brand, form and strength you need, and confirm the batch you are quoted against before committing a tender timeline. Global demand for GLP-1 receptor agonists remains strong across both indications, so buyers should plan enquiries and registration renewals with that demand context in mind rather than assuming open-market availability at all times.
Does M Care hold WHO-GMP or WHO-PQ certification directly?
No. M Care Exports is a merchant-exporter, not a manufacturer, and does not hold WHO-GMP or WHO-PQ certification itself. We source semaglutide from WHO-GMP certified Indian manufacturers and pass the manufacturer's certification and batch documentation through with every order. Our own credentials are ISO 9001:2015 certification and a CDSCO export licence.
Is a generic or biosimilar version of semaglutide available for our market?
Semaglutide is still under originator patent protection in most major destination markets, so sourcing currently centers on the branded, licensed product from the originator's licensed manufacturing network. Patent and registration status varies by country and should be verified for your specific destination before you commit a tender or registration filing; we can quote against whichever position applies.
Who stands behind this page, and where its statements come from.
Reviewed by Dr. Rajat Bhatt, PharmD, Managing Director, M Care Exports. Last reviewed 2026-08-22.
This page is sourcing information for licensed importers, hospital procurement and tender desks. It is not medical, pharmaceutical or prescribing advice, and it is not a substitute for the approved product information of the line on your order. See our full disclaimer.
Send the specifics. You'll have a price inside one working day.
Form and strength, destination market and indicative volume. The Mumbai desk replies within one working day, including when the honest answer is that the route is not viable yet.